OncoMatch/Clinical Trials/NCT04772456
Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas
Is NCT04772456 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Hyperpolarized 13C-Pyruvate for glioma.
Treatment: Hyperpolarized 13C-Pyruvate — The purpose of this study is to examine the safety and feasibility of performing hyperpolarized metabolic MRI in the diagnosis of brain tumor. This study will also assess the accuracy of hyperpolarized metabolic MRI to diagnose intermediate to patients with infiltrating gliomas and examine the added utility of metabolic MRI over standard MRI imaging The FDA is allowing the use of hyperpolarized \[1-13C\] pyruvate (HP 13C-pyruvate) in this study. Up to 5 patients may take part in this study at the University of Maryland, Baltimore (UMB).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Demographics
Lab requirements
Kidney function
sufficient to receive iv contrast
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Rosy Njonkou Tchoquessi · Baltimore, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04772456 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages